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Human BarH-like homeobox 2 (Barx2), a homeodomain factor of the Bar family, has an important role in
controlling the expression of cell adhesion molecules and has been reported in an increasing array of
tumor types except colorectal cancer (CRC). The purpose of the current study was to characterize the
expression of Barx2 and assess the clinical signiﬁcance of Barx2 in CRC. First, we analyzed the expression
of Barx2 in two independent public datasets from Oncomine. Subsequently, we evaluated Barx2 mRNA
and protein expression by quantitative real-time PCR and western blotting, respectively. It was deter-
mined that Barx2 expression was lower in tumor tissues than in adjacent non-tumorous colorectal tis-
sues of CRC patients, consistent with results from the public datasets. Subsequently, a tissue microarray
containing 196 CRC specimens was evaluated for Barx2 expression by immunohistochemical staining. It
was found that low expression of Barx2 signiﬁcantly correlated with TNM stage, AJCC stage, differenti-
ation, and relapse in patients with CRC. Patients with lower levels of Barx2 expression showed reduced
disease-free survival and overall survival. Furthermore, a trend toward shorter overall survival in the
patient group with Barx2-negative tumors independent of advanced AJCC stage and poor differentiation
was determined by Kaplan-Meier survival analysis. Based on univariate and multivariate analyses, Barx2
expression was an independent prognostic factor for determining CRC prognosis. Taken together, low
Barx2 expression was associated with the progression of CRC and could serve as a potential independent
prognostic biomarker for patients with CRC.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is the third most common cancer and
the fourth leading cause of cancer mortality worldwide [1]. Despite
various advances in its diagnosis and treatment over the past de-
cades, the prognosis for CRC patients remains poor partially owingrgery, Shanghai General Hos-
ity, 85 Wujin Road, 200080
, sunshinezsl1989@163.com
, zhangdongyuan@163.com
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Inc. This is an open access article uto its high recurrence rate [2,3]. Tumor metastasis is a signiﬁcant
factor in the management of colorectal cancer and is a major
obstacle to successful treatment [4]. To date, no biomarkers have
been found that efﬁciently predict the prognosis of CRC in the
clinics. Hence, identiﬁcation and use of novel biomarkers associ-
ated with CRC for early detection and to assess malignancy is
essential to improve prognosis in CRC patients.
As a homeodomain factor of the Bar family, BarH-like homeobox
2 (Barx2) regulates factors that control the expression of cell
adhesion molecules and inﬂuences cellular differentiation in
various developmental contexts [5,6]. The gene encoding human
Barx2 maps to chromosome 11q25 and has four exons, ranging
from 85 to 1099 bp [7]. As a transcription factor controlling cell
adhesion and cytoskeleton remodeling [8], downregulation of
Barx2 is associated with a number of solid tumors and is correlated
with poor prognosis [9,10]. However, little is known about Barx2 innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinicopathologic characteristics of 196 colorectal cancer
patients.
Characteristics N (%)
Age (yr)
<65 78 (39.8)
>¼65 118 (60.2)
Gender
Male 85 (43.4)
Female 111 (56.6)
Tumor location
Right 82 (41.8)
Transverse 19 (9.7)
Left 17 (8.7)
Sigmoid 78 (39.8)
T classiﬁcation
T 1 6 (3.1)
T 2 23 (11.7)
T 3 73 (37.2)
T 4 94 (48.0)
N classiﬁcation
N 0 105 (53.6)
N 1 57 (29.1)
N 2 34 (17.3)
M classiﬁcation
M 0 174 (88.8)
M 1 22 (11.2)
AJCC stage
I 23 (11.7)
II 79 (40.3)
III 77 (39.3)
IV 17 (8.7)
Vascular invasion
No 182 (92.9)
Yes 14 (7.1)
Differentiation
Well 97 (49.5)
Moderate 69 (35.2)
Poor 30 (15.3)
Relapse
No 116 (59.2)
Yes 73 (37.2)
AJCC American Joint Committee on Cancer.
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and shows a graded pattern of expression in intestinal enterocytes,
decreasing in the crypt-to-villous direction [11]. The clinicopatho-
logical signiﬁcance of Barx2 and its prognostic value in CRC remains
unknown.
In this study, the expression of Barx2 in CRC was investigated at
both the mRNA and protein levels. Moreover, we analyzed Barx2
protein expression using a tissue microarray (TMA) with data from
196 patients to examine the correlation between expression and
clinicopathologic parameters of CRC. The present study tested the
hypothesis that Barx2 acts as a tumor suppressor; data regarding
Barx2 expression in these patients will provide information for its
usefulness as a biomarker for diagnosing and assessing the prog-
nosis of CRC.
2. Materials and methods
2.1. Patients and tissue specimens
All patient-derived specimens were collected, formalin-ﬁxed,
parafﬁn-embedded, and used under protocols approved by the
Institutional Review Boards of Shanghai General Hospital. No pa-
tients had received radiotherapy, chemotherapy or other related
anti-tumor therapies before the surgery. Diagnosis was conﬁrmed
by at least two pathologists and the histology and clinical stages
were classiﬁed according to the guidelines of NCCN2010. The
clinicopathologic characteristics of patients are summarized in
Table 1. Overall survival (OS) and disease-free survival (DFS) rates
were deﬁned as the interval between initial surgery and clinically
or radiologically determined recurrence/metastasis and death,
respectively. All patients provided informed consent according to a
protocol approved by the Institutional Review Board of Shanghai
General Hospital, School of Medicine, Shanghai Jiaotong University.
2.2. Tissue microarray (TMA) construction
A total of 196 cases, including primary CRC tumors paired with
normal mucosa, were retrieved from the archives of the Depart-
ment of Pathology, Shanghai General Hospital, and were used to
construct the TMA. Tissue morphology was validated by hema-
toxylin and eosin (H&E) staining and cores (2.0 mm diameter) were
punched from the parafﬁn blocks. To ensure similar reaction con-
ditions, paired cores punched from the same patient were spotted
next to each other as previously reported [12]. All specimens were
examined by two pathologists to prevent bias.
2.3. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from fresh CRC tissues and the adjacent
normal mucosa using TRIzol reagent (TaKaRa, Japan) according to
the manufacturer's instructions. Specimens were collected from
the Department of General Surgery, Shanghai General Hospital
during 2015. The RevertAid First Strand cDNA Synthesis Kit (Fer-
mentas, USA) was used to reverse transcribe 2 mg of RNA according
to the manufacturer's recommendations. qRT-PCR assays were
performed using 4 ml of cDNA (1:10 dilution) and SYBR green
(TaKaRa) in a total volume of 20 ml, using the ABI 7900 Real-time
PCR System (ABI, USA). Primers sequences used for Barx2 detec-
tion were as follows: forward 50- ATG ATC GAC GAG ATC CTC TC-30
and reverse 50- GCT TAA TGG TGG GGG TTC CG-30. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as an internal
control, and primer sequences were as follows: forward 50- GGG
AAG GTG AAG GTC GGA GT-30 and reverse 50- GGG GTC ATT GAT
GGC AAC A-30. Each PCR product was run in triplicate, and the
relative Barx2 mRNA level was calculated by the 2DDCt method.2.4. Western blot (WB) analysis
Protein from tissue was extracted using RIPA lysis buffer with
the inhibitor phenylmethanesulfonyl ﬂuoride (Beyotime Biotech-
nology, Jiangsu, China) and protein concentration was measured
using the BCA protein assay kit (Beyotime Biotechnology) according
to the manufacturer's instructions. Equal amounts of protein
(30 mg) were separated on 10% SDS-PAGE gels and transferred onto
PVDF membranes (Millipore, Billeria, MA). After blocking with 5%
shim milk in TBST buffer for 1.5 h at 27 C, membranes were
incubated overnight at 4 C with an anti-Barx2 primary antibody
(1:200 dilution; Santa Cruz, CA, USA). An anti-GAPDH antibody
(1:1000 dilution; Santa Cruz, CA, USA) was used as the loading
control. After incubation with a secondary antibody for 2 h at room
temperature, proteins were detected using ECL regent (Millipore,
Billeria, MA).2.5. Immunohistochemical (IHC) staining
Slides were ﬁrst baked at 60 C for 2 h, and then slides were de-
waxed in xylene, and rehydrated in graded series of ethanol fol-
lowed by heat-induced antigen retrieval in 0.01 M sodium citrate
buffer (PH 6.0) for 4 min. After blocking endogenous peroxidase
with 3% H2O2, the TMA sections were then incubated with the
primary antibody against Barx2 (1:100 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at 4 C overnight. Following re-
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conjugated secondary detection antibodies (Dako Cytomation,
Glostrup, Denmark) at 27 C for 30 min. Finally, the sections, were
rinsed in PBS, incubated with DAB, counterstained with Mayer's
hematoxylin, dehydrated, and mounted. Two investigators, blinded
to patient prognosis, evaluated the staining and the sum of the
staining intensity. The staining extent scores were used as the ﬁnal
staining score [13]. In the event of a discrepancy in scoring, the
slides were simultaneously reexamined by two pathologists using a
multi-head microscope until consensus was achieved.2.6. Statistical analysis
Data analysis was performed using the SPSS 22.0 statistical
software package (SPSS, Chicago, IL, USA). Barx2 mRNA expression
in fresh CRC tissues and normal colon mucosa was analyzed by a
student's t-test. The c2 test or Fisher's exact test was appropriately
used to determine the association between Barx2 expression and
clinicopathological variables of CRC. Survival curves were plotted
using the Kaplan-Meier method with the log-rank test employed to
compare differences. The hazard ratio (HR), with a 95% conﬁdence
interval, in Cox proportional hazard regressions were applied to
estimate the hazard risk of the individual factors DFS and OS. For all
tests, a P-value < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Decreased expression of Barx2 in CRC tissues
First, we analyzed the expression of Barx2 in two independentFig. 1. Expression of Barx2 in CRC tissues and paired normal mucosa. a. Barx2 expre
adenocarcinoma (1), colon adenocarcinoma (2), colon mucinous adenocarcinoma (3), recta
noma (6), and rectosigmoid mucinous adenocarcinoma (7). b. Barx2 expression at the RNA l
(1) and colorectal adenocarcinoma (2). c. Quantitative real-time PCR detection of relative ex
blot analysis of Barx2 protein expression in eight representative paired CRC tissues, with G
protein levels, normalized to levels of GAPDH; *P < 0.05, **P < 0.01, compared to 3T.publicly available datasets from Oncomine (https://www.
oncomine.org/resource/main.html) [14,15], and found that the
mRNA expression of Barx2 in CRC tissues was markedly lower than
that in matched normal mucosa (Fig. 1aeb). Subsequently, by qRT-
PCR, the expression level of Barx2 was analyzed in 40 randomly
selected paired specimens from Shanghai General Hospital, and
showed signiﬁcant down-regulation in CRC compared to that in
paired non-tumor tissues (Fig. 1c), consistent with aforementioned
observations. We then further analyzed the impact of aberrant
expression of Barx2 at the RNA level on CRC patient survival using
the public database from TCGA. However, no signiﬁcant association
was found between the expression of Barx2 (at the RNA level) and
OS, regardless of classiﬁcation (Fig. S1), suggesting that Barx2
expression might be associated with CRC tumorigenesis at the
protein level rather than at the RNA level. WB analysis further
conﬁrmed that Barx2 was down-regulated in CRC tissues compared
to that in the corresponding normal mucosa (Fig. 1d).3.2. Correlation between Barx2 expression and clinicopathological
characteristics of CRC
IHC analysis was conducted to investigate the correlation be-
tween Barx2 protein levels and clinical factors of CRC using a TMA
that contained 196 cases of primary CRC tissues paired with normal
mucosa. Barx2 was primarily localized in the nucleus of CRC cells;
representative IHC staining of Barx2 in CRC tissue and the normal
mucosa are summarized in Fig. 2. The rates of strong positive, weak
positive, and negative staining in normal colorectal mucosa were
114/196 (58.2%), 66/196 (33.7%), and 16/196 (8.2%), respectively
(Table 2). In contrast, low expression of Barx2 was observed in thession at the RNA level in TCGA colorectal samples grouped by no value (0), cecum
l adenocarcinoma (4), rectal mucinous adenocarcinoma (5), rectosigmoid adenocarci-
evel in the Skrzypczak Colorectal dataset grouped by no value (0), colorectal carcinoma
pression of Barx2 in 40 human CRC tissues and paired non-tumor mucosa. d. Western
APDH used as the loading control. e. Quantiﬁcation of western blot analysis of Barx2
Fig. 2. Representative immunohistochemistry staining of Barx2 in CRC tissues and non-tumor colorectal mucosa. A-a. Strong Barx2 staining in non-tumor colorectal mucosa;
B-b. Moderate Barx2 staining in well-differentiated CRC C-c. Weak Barx2 staining in moderately differentiated CRC; D-d. Negative Barx2 staining in poorly differentiated CRC; E-e:
Negative Barx2 staining in metastatic lymph node; F-f. Elevated Barx2 staining in lymph node without metastasis. AeF. Original magniﬁcation, 50; aef. original
magniﬁcation, 200.
Table 2
Expression of Barx2 in normal colon mucosa and primary cancerous tissues.
Tissue sample N Expression of Barx2 P value
Negative (n, %) Weak positive (n, %) Strong positive (n, %)
Normal mucosa 196 16 (8.2) 66 (33.7) 114 (58.2) <0.001a
Tumor tissue 196 93 (47.4) 73 (37.2) 30 (15.3)
a Signiﬁcant difference in the expression of Barx2 between normal colon mucosa and cancerous tissues.
Table 3
Association between Barx2 expression and clinicopathological characteristics in colorectal cancer (n ¼ 196).
Variable N Barx2 expression P value
Negative (93) Weak positive (73) Strong positive (30)
Age (yr)
<65 78 40 (51.3%) 25 (32.1%) 13 (16.7%) 0.473
>¼65 118 53 (44.9%) 48 (40.7%) 17 (14.4%)
Gender
Male 85 38 (44.7%) 34 (40.0%) 13 (15.3%) 0.762
Female 111 55 (49.5%) 39 (35.1%) 17 (15.3%)
Tumor location
Right 82 41 (50.0%) 29 (35.4%) 12 (14.6%) 0.513
Transverse 19 10 (52.6%) 6 (31.6%) 3 (15.8%)
Left 17 8 (47.1%) 9 (52.9%) 0 (0.0%)
Sigmoid 78 34 (43.6%) 29 (37.2%) 15 (19.2%)
T classiﬁcation
T 1 6 0 (0.0%) 3 (50.0%) 3 (50.0%) <0.001a
T 2 23 7 (30.4%) 9 (39.1%) 7 (30.4%)
T 3 73 20 (27.4%) 35 (47.9%) 18 (24.7%)
T 4 94 66 (70.2%) 26 (27.7%) 2 (2.1%)
N classiﬁcation
N 0 105 39 (37.1%) 43 (41.0%) 23 (21.9%) 0.001a
N 1 57 28 (49.1%) 23 (40.4%) 6 (10.5%)
N 2 34 26 (76.5%) 7 (20.6%) 1 (2.9%)
M classiﬁcation
M 0 174 77 (44.3%) 68 (39.1%) 29 (16.7%) 0.037a
M 1 22 16 (72.7%) 5 (22.7%) 1 (4.5%)
AJCC stage
I 23 5 (21.7%) 11 (47.8%) 7 (30.4%) 0.006a
II 79 31 (39.2%) 32 (40.5%) 16 (20.3%)
III 77 46 (59.7%) 25 (32.5%) 6 (7.8%)
IV 17 11 (64.7%) 5 (29.4%) 1 (5.9%)
Vascular invasion
No 182 83 (45.6%) 69 (37.9%) 30 (16.5%) 0.109
Yes 14 10 (71.4%) 4 (28.6%) 0 (0.0%)
Differentiation
Well 97 32 (33.0%) 42 (43.3%) 23 (23.7%) <0.001a
Moderate 69 39 (56.5%) 23 (33.3%) 7 (10.1%)
Poor 30 22 (73.3%) 8 (26.7%) 0 (0.0%)
Relapse
No 116 47 (40.5%) 44 (37.9%) 25 (21.6%) 0.018a
Yes 73 40 (54.8%) 28 (38.4%) 5 (6.8%)
a Signiﬁcant difference.
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Fig. 3. The prognostic signiﬁcance of Barx2 in CRC patients assessed by Kaplan-Meier analysis. DFS (a) and OS (b) were signiﬁcantly poorer in patients with Barx2-negative
expression than in those with Barx2-positive expression. Comparisons of OS between patients with Barx2-negative expression and those with Barx2-positive expression in an
early AJCC stage (I-II) cohort and in an advanced AJCC stage (III-IV) cohort (c-d) and in patients with well-differentiated tumor and in those with moderate and poor differentiation
(e-f). P-values were calculated by the log-rank test and P < 0.05 denoted signiﬁcance.
Table 4
Univariate and multivariate analysis of overall survival in colorectal cancer.
Overall survival
Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Age (yr) 0.992 (0.974e1.011) 0.418
Gender 1.453 (0.873e2.419) 0.150
Tumor location 1.080 (0.903e1.292) 0.397
T classiﬁcation 2.696 (1.739e4.178) 0.001a 1.490 (0.917e2.421) 0.108
N classiﬁcation 3.701 (2.679e5.112) 0.024a 2.340 (1.402e3.905) 0.001a
M classiﬁcation 4.005 (2.563e5.176) 0.001a 2.886 (1.945e3.101) <0.001a
UICC stage 5.069 (3.388e7.586) 0.004a 0.497 (0.257e0.963) 0.038a
Vascular invasion 4.274 (2.213e8.255) 0.084
Differentiation 2.840 (2.049e3.937) <0.001a 1.286 (0.842e1.964) 0.244
Relapse 3.663 (2.556e4.573) <0.001a 2.004 (1.375e3.772) <0.001a
Barx2 0.513 (0.348e0.758) 0.001a 0.920 (0.557e1.518) 0.006a
HR hazard ratio; CI conﬁdence interval.
a P < 0.05 indicate that the 95% CI of HR was not including 1.
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specimens, weak staining in 73/196 (37.2%) specimens, and nega-
tive staining in 93/196 (47.4%) specimens (Table 2). Furthermore, in
the available lymph nodes (LN) of CRC patients, signiﬁcantly lower
positive Barx2 staining was observed in metastatic LNs compared
to those without metastasis (Fig. 2eef).
The relationship between Barx2 expression and clinicopatho-
logic features in CRC is summarized in Table 3. Downregulation of
Barx2 in CRC was markedly correlated with T classiﬁcation
(P < 0.001), N classiﬁcation (P¼ 0.001), M classiﬁcation (P¼ 0.037),
AJCC stage (P ¼ 0.006), histological differentiation (P < 0.001), and
tumor relapse (P ¼ 0.018). However, no signiﬁcant association was
found between Barx2 expression and other clinical parameters,
such as age, gender, tumor location, or vascular invasion, in the
present study (P > 0.05 for all, Table 3). Taken together, these data
indicate that downregulation of Barx2 is associated with an
aggressive CRC phenotype.
3.3. Association between Barx2 expression and prognosis in CRC
patients after curative surgery
To test the prognositic value of Barx2 for CRC, disease-free sur-
vival (DFS) and overall survival (OS) were assessed by Kaplan-Meier
survival analysis and these parameters were compared using the
log-rank test. As shown in Fig. 3aeb, patients with lower Barx2
expression had poorer DFS (P ¼ 0.009) and OS (P ¼ 0.002) than
those with higher Barx2 expression. To further conﬁrm theTable 5
Univariate and multivariate analysis of disease-free survival in colorectal cancer.
Disease-free survival
Univariate analysis
HR (95%CI) P
Age (yr) 0.978 (0.578e1.656) 0
Gender 1.348 (0.793e2.291) 0
Tumor location 1.142 (0.944e1.382) 0
T classiﬁcation 2.536 (1.616e3.979) <
N classiﬁcation 2.691 (2.637e5.187) 0
M classiﬁcation 6.241 (4.347e8.602) <
UICC stage 3.966 (2.604e6.040) <
Vascular invasion 4.645 (2.328e9.267) 0
Differentiation 2.556 (1.815e3.599) <
Relapse 4.345 (3.602e5.880) <
Barx2 0.551 (0.369e0.823) 0
HR hazard ratio; CI conﬁdence interval.
a P < 0.05 indicate that the 95% CI of HR was not including 1.association between Barx2 expression and CRC metastases or local
relapse, regardless of clinical stage, we performed subgroup ana-
lyses for OS according to AJCC stages and histological differentia-
tion. Interestingly, a statistical difference was observed between
positive and negative Barx2 staining groups for both low-stage (I-II;
P ¼ 0.990) and advanced-stage (III-IV; P ¼ 0.033) CRC patients
(Fig. 3ced). In addition, in CRC patients with moderate and poor
differentiation, lower Barx2 expression exhibited an obvious rela-
tionship with decreased OS (P ¼ 0.048; Fig. 3f), whereas in patients
with well-differentiated tumor, down-regulated Barx2 expression
did not apparently affect OS (P ¼ 0.694, Fig. 3e).
Subsequently, based on univariate Cox regression analyses, T
classiﬁcation, N classiﬁcation, M classiﬁcation, AJCC stage, differ-
entiation, tumor relapse, and Barx2 expression were signiﬁcantly
associated with both OS and DFS (Tables 4 and 5). Furthermore,
multivariate analysis, used to analyze parameters with signiﬁcance
based on univariate analyses, demonstrated that Barx2 expression
remained an independent prognostic factor for increased disease
recurrence and decreased survival in CRC (Tables 4 and 5).
4. Discussion
Homeobox genes have been reported to be essential for the
correct positioning and differentiation of tissues and organs in
diverse species [16,17]. All homeobox genes encode a 61-amino
acid DNA binding structure called the homeodomain, that act as
transcription factors to control the activity of other genes [18e20].Multivariate analysis
value HR (95%CI) P value
.935
.270
.171
0.001a 1.675 (0.991e2.831) 0.054
.037a 2.439 (1.404e4.236) 0.002a
0.001a 4.705 (3.692e5.512) <0.001a
0.008a 0.401 (0.188e0.851) 0.017a
.079
0.001a 1.185 (0.805e1.742) 0.389
0.001a 2.162 (1.745e4.041) <0.001a
.004a 0.914 (0.553e1.510) 0.025a
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regulate the expression of cell adhesion molecules (CAMs)
including NCAM and cadherin 6 [5,9], suggesting that it is involved
in cell processes such as cell aggregation, formation of intercellular
contacts, and cell fusion. To date, human Barx2 has been described
as a tumor suppressor gene, and downregulation of Barx2 expres-
sion was shown to correlate with invasiveness and poor clinical
outcome in several solid tumors [9,10]. As reported, Barx2 is
expressed throughout the gut and is located in epithelial cells of the
proliferative and differentiative regions of the stomach, esophagus,
and intestine [11]. However, the Barx2 expression pattern and its
correlation with clinicopathological parameters and prognosis in
CRC remain unknown. In the present study, we demonstrated that
the expression of Barx2 was much lower in CRC tissues than in
corresponding human normal mucosa, and that downregulation of
Barx2 was a novel independent prognostic biomarker for CRC.
In our study, consistent with the results of two publicly available
datasets from Oncomine, we conﬁrmed that the expression of
Barx2 was markedly downregulated in CRC tissues compared to
that in adjacent normal colorectal mucosa at both the transcrip-
tional and posttranscriptional levels. Furthermore, according to IHC
analysis in the TMA, strong positive expression of Barx2 was more
apparent in normal colorectal mucosa (58.2%,114/196) compared to
that in primary CRC specimens (15.3%, 30/196). In addition, Barx2
positive staining was markedly reduced in metastatic LNs
compared to that in those without metastasis, suggesting that
lower expression of Barx2might be associatedwith CRCmetastasis.
Previous studied of ovarian cancer and primary hepatocellular
carcinoma showed that low expression of Barx2 was signiﬁcantly
correlated with metrics of tumor malignancy and poor prognosis
[9,10]. Herein, we discovered a similar phenomenon in which low
expression of Barx2 in CRC was strikingly associated with various
clinicopathological characteristics, such as T classiﬁcation, N clas-
siﬁcation, M classiﬁcation, AJCC stage, histological differentiation,
and tumor relapse. In addition, based on Kaplan-Meier survival
analysis, we demonstrated that Barx2-negative tumors were
associated with poorer DFS and OS, when compared to Barx2-
positive tumors. Subsequently, both univariate and multivariate
analysis veriﬁed that Barx2 expression was an independent prog-
nostic marker for DFS and OS in CRC patients after curative surgery.
Most importantly, for the ﬁrst time, we showed that aberrant
downregulation of Barx2 was markedly correlated with shorter OS
in cased with advanced AJCC stage and poor tumor differentiation.
These discoveries further conﬁrmed that downregulation of Barx2
contributes to an aggressive CRC phenotype.
In summary, we demonstrated for the ﬁrst time that aberrant
downregulation of Barx2 is signiﬁcantly correlated with an
aggressive phenotype and poor prognosis in human CRC, suggest-
ing that Barx2 might serve as a novel independent biomarker and
potential therapeutic target for this disease. Barx2 was reported to
be involved in Wnt Signaling and ras/raf signaling [22,23]; in this
study, we did not extensively study the mechanism associated with
downregulation of Barx2 in CRC; this requires further investigation.
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